2025-2026 Regular SessionIllinois Legislature

HB3637: HEALTH REGULATION-VARIOUS

Legislative Summary

Amends the Behavior Analyst Licensing Act, the Clinical Psychologist Licensing Act, the Clinical Social Work and Social Work Practice Act, the Marriage and Family Therapy Licensing Act, the Medical Practice Act of 1987, the Licensed Certified Professional Midwife Practice Act, the Nurse Practice Act, the Pharmacy Practice Act, the Physician Assistant Practice Act of 1987, the Professional Counselor and Clinical Professional Counselor Licensing and Practice Act, the Wholesale Drug Distribution Licensing Act, the Registered Surgical Assistant and Registered Surgical Technologist Title Protection Act, and the Genetic Counselor Licensing Act. Provides that the Department of Professional and Financial Regulation shall not take any disciplinary or non-disciplinary action against a person's authorization to practice (rather than against the license or permit issued) under each of the amended Acts based solely upon the person's involvement in any health care service, so long as the care was not unlawful under the laws of the State. Prohibits the Department from taking any disciplinary or non-disciplinary action against a person's authorization to practice (rather than against the license or permit issued) under each of the amended Acts based upon the person's license, registration, or permit (rather than only license) being revoked or suspended, or the person being otherwise disciplined by any other state, if that form of discipline was based solely on the person violating another state's laws prohibiting involvement in any health care service if that health care service would not have been unlawful under the laws of the State and is consistent with the applicable standard of conduct for a person practicing in Illinois under those Acts. Changes certain references to official occupation titles in the amended Acts to "person". Amends the Illinois Food, Drug and Cosmetic Act. Provides that a drug's status as not approved by the U.S. Food and Drug Administration shall not cause it to be deemed an adulterated drug if its safety and efficacy have been established by peer-reviewed research or if it is recommended for use by the World Health Organization, even if the drug's labelling reflects prior approval that is no longer in effect, so long as such labelling was true and accurate at the time of manufacture.

Demographic Impact

Overall analysis of equity impact

Neutral
Medium ConfidenceView detailed demographic breakdown ↓

Unlock Full Demographic Insights

Go beyond the overall score.

Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.

Enable full analysis features for your organization.

Contact Sales to Learn More

Or email us directly at sales@legiequity.us.

Bill History

2/7/2025
Filed with the Clerk by Rep. Dagmara Avelar
House of Representatives
2/18/2025
First Reading
House of Representatives
2/18/2025
Referred to Rules Committee
House of Representatives
3/11/2025
Assigned to Health Care Availability & Accessibility Committee
House of Representatives
3/13/2025
Added Co-Sponsor Rep. Joyce Mason
House of Representatives
3/13/2025
Added Co-Sponsor Rep. Nabeela Syed
House of Representatives
3/13/2025
Added Co-Sponsor Rep. Abdelnasser Rashid
House of Representatives
3/13/2025
Added Co-Sponsor Rep. Aarón M. Ortíz
House of Representatives
3/13/2025
Added Co-Sponsor Rep. Edgar González, Jr.
House of Representatives
3/13/2025
Added Co-Sponsor Rep. Barbara Hernandez
House of Representatives
3/18/2025
Added Co-Sponsor Rep. Nicolle Grasse
House of Representatives
3/18/2025
Added Co-Sponsor Rep. Anna Moeller
House of Representatives
3/18/2025
Added Co-Sponsor Rep. Lindsey LaPointe
House of Representatives
3/18/2025
Added Co-Sponsor Rep. Margaret Croke
House of Representatives
3/18/2025
Added Co-Sponsor Rep. Eva-Dina Delgado
House of Representatives
3/18/2025
Added Co-Sponsor Rep. Kimberly Du Buclet
House of Representatives
3/18/2025
Added Co-Sponsor Rep. Yolonda Morris
House of Representatives
3/18/2025
Added Co-Sponsor Rep. Jennifer Gong-Gershowitz
House of Representatives
3/18/2025
Added Co-Sponsor Rep. Sharon Chung
House of Representatives
3/18/2025
Added Co-Sponsor Rep. Will Guzzardi
House of Representatives
3/18/2025
Added Co-Sponsor Rep. Mary Beth Canty
House of Representatives
3/18/2025
Added Chief Co-Sponsor Rep. Kelly M. Cassidy
House of Representatives
3/18/2025
Added Chief Co-Sponsor Rep. Jehan Gordon-Booth
House of Representatives
3/18/2025
Added Chief Co-Sponsor Rep. Robyn Gabel
House of Representatives
3/18/2025
Added Chief Co-Sponsor Rep. Bob Morgan
House of Representatives
3/18/2025
Do Pass / Short Debate Health Care Availability & Accessibility Committee; 009-005-000
House of Representatives
3/19/2025
Added Co-Sponsor Rep. Michael Crawford
House of Representatives
3/19/2025
Placed on Calendar 2nd Reading - Short Debate
House of Representatives
3/19/2025
House Floor Amendment No. 1 Filed with Clerk by Rep. Dagmara Avelar
House of Representatives
3/19/2025
House Floor Amendment No. 1 Referred to Rules Committee
House of Representatives
3/20/2025
House Floor Amendment No. 1 Rules Refers to Health Care Availability & Accessibility Committee
House of Representatives
3/25/2025
House Floor Amendment No. 1 Recommends Be Adopted Health Care Availability & Accessibility Committee; 008-003-000
House of Representatives
3/26/2025
Second Reading - Short Debate
House of Representatives
3/26/2025
Held on Calendar Order of Second Reading - Short Debate
House of Representatives
4/7/2025
House Floor Amendment No. 1 Adopted by Voice Vote
House of Representatives
4/7/2025
Placed on Calendar Order of 3rd Reading - Short Debate
House of Representatives
4/7/2025
Added Co-Sponsor Rep. Maura Hirschauer
House of Representatives
4/7/2025
Added Co-Sponsor Rep. Janet Yang Rohr
House of Representatives
4/7/2025
Third Reading - Short Debate - Passed 067-039-000
House of Representatives
4/7/2025
Added Co-Sponsor Rep. Natalie A. Manley
House of Representatives
4/8/2025
Arrive in Senate
Senate
4/8/2025
Placed on Calendar Order of First Reading
Senate
4/8/2025
Chief Senate Sponsor Sen. Karina Villa
Senate
4/8/2025
First Reading
Senate
4/8/2025
Referred to Assignments
Senate
4/23/2025
Assigned to Executive
Senate

Amendments

House Amendment 001

House Amendment 001

3/19/2025Not Adopted

Roll Call Votes

Third Reading in House
4/7/2025
67
Yea
39
Nay
1
Not Voting
0
Absent
Result: PASSED